Defining SOD1 ALS natural history to guide therapeutic clinical trial design.
about
Differentiating lower motor neuron syndromesNuclear export of misfolded SOD1 mediated by a normally buried NES-like sequence reduces proteotoxicity in the nucleus.Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutationsRandomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS.Fingerprint analysis of Huolingshengji Formula and its neuroprotective effects in SOD1G93A mouse model of amyotrophic lateral sclerosis.Natural history and the dawning of a new era for familial ALS.
P2860
Defining SOD1 ALS natural history to guide therapeutic clinical trial design.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Defining SOD1 ALS natural history to guide therapeutic clinical trial design.
@en
Defining SOD1 ALS natural history to guide therapeutic clinical trial design.
@nl
type
label
Defining SOD1 ALS natural history to guide therapeutic clinical trial design.
@en
Defining SOD1 ALS natural history to guide therapeutic clinical trial design.
@nl
prefLabel
Defining SOD1 ALS natural history to guide therapeutic clinical trial design.
@en
Defining SOD1 ALS natural history to guide therapeutic clinical trial design.
@nl
P2093
P2860
P50
P356
P1476
Defining SOD1 ALS natural history to guide therapeutic clinical trial design.
@en
P2093
Alan Pestronk
April L McVey
Brian Callaghan
Glenn Lopate
James P Wymer
Jennifer Jockel-Balsarotti
Jingxia Liu
Jonathan D Glass
Kevin B Boylan
Leo F McCluskey
P2860
P304
P356
10.1136/JNNP-2016-313521
P407
P577
2016-06-03T00:00:00Z